Table 1.
Study cohort characteristics: demographic, clinical and biological data. A total of 50 people with cystic fibrosis (PWCF) were included.
| PWCF Characteristics | Percentage (n) | |
|---|---|---|
| Age group (years) | ≤6 | 4 (2) |
| 7–13 | 8 (4) | |
| 14–18 | 6 (3) | |
| 19–25 | 28 (14) | |
| 26–30 | 22 (11) | |
| ≥30 | 32 (16) | |
| Sex | Female | 48 (24) |
| Male | 52 (26) | |
| p.F508del mutation | Homozygote | 60 (30) |
| Heterozygote | 28 (14) | |
| Other mutations | 12 (6) | |
| Lung function (FEV1 %) | ≤40 | 26 (13) |
| 40–70 | 52 (26) | |
| >70 | 22 (11) | |
| Chronic antibiotic administration |
Azithromycin | 44 (22) |
| Aztreonam | 10 (5) | |
| Colistin | 42 (21) | |
| Tobramycin | 20 (10) | |
| Antibiotics administration one month before the sample | Oral * | 36 (18) |
| Intravenous ** | 16 (8) | |
* amoxicillin/clavulanic acid, cefpodoxime, ciprofloxacin, doxycycline, linezolid, minocycline, pristinamycin, trimetoprim/sulfamethoxazole, ** amikacin, aztreonam, ceftazidime, doxycycline, linezolid, meropenem, piperacillin/tazobactam, tobramycin, trimetoprim/sulfamethoxazole, FEV1: Forced Expiratory Volume in one second.